RavenQuest & McGill University continue their research into environmentally sustainable methods of yield maximization and disease resistance in the cannabis plant. Front. Microbiol., 08 August 2019 Plant Growth-Promoting Rhizobacteria for Cannabis Production: Yield, Cannabinoid Profile and Disease Resistance https://www.frontiersin.org/articles/10.3389/fmicb.2019.01761/full
RavenQuest BioMed (CNSX:RQB) Gains Momentum as Investors Discover Cutting Edge Technology Alessandro Bruno | 51 mins ago https://midasletter.com/2019/08/rav...s-investors-discover-cutting-edge-technology/
RavenQuest Signs European Joint Venture With Cannabis Biocare September 03, 2019 06:00 ET | Source: RavenQuest BioMed Inc. VANCOUVER, British Columbia, Sept. 03, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest”), one of Canada’s most innovative cannabis producers, is pleased to announce it has signed a Joint Venture Agreement with Cannabis Biocare to construct cannabis cultivation facilities with planned capacity to produce 35,000 kilograms of medical cannabis in Europe. The Joint Venture plans to initially build two cannabis cultivation facilities in Portugal, with an option for further expansion across Europe and beyond. Two sites have been selected, both of which are well-suited for retrofit, in the Portuguese towns of Vila Nogueira de Azeitao and Porto. RavenQuest owns a 50% stake in the Joint Venture, which is expected to be called “RQBeu”. Under the terms of the Joint Venture Agreement, Cannabis Biocare will endeavor to obtain full funding for cannabis production facility build-outs and cannabis technologies, including orbital gardens, and start-up expenses for the Joint Venture. RavenQuest will grant the Joint Venture use of its Orbital Garden grow technology, cultivation expertise, intellectual property and beneficial microbes developed by RavenQuest in connection with its partnership involving McGill University. Commenting on the deal, RavenQuest CEO, George Robinson, stated, “We are very pleased to enter into this Joint Venture. Europe is a huge marketplace with over 700 million residents and a progressive attitude toward cannabis legalization. Many European nations already allow for medical cannabis consumption, with many more moving toward adult use legalization. Portugal is one of the most attractive of these nations, and an excellent fit to establish RavenQuest’s first European facilities. “Our plans to produce 35,000 kilograms in Europe are now taking shape in the form of a definitive agreement with our partners at Cannabis Biocare and the identification of two existing buildings, which are ready for immediate retrofit. Our partner is responsible for providing 100% of the funding for the Joint Venture, which allows for non-dilutive expansion into this burgeoning market. In addition, Cannabis Biocare’s political relationships across Europe, North Africa and the Gulf States brings the potential for future expansion as these markets mature,” Robinson continued. https://www.globenewswire.com/news-...pean-Joint-Venture-With-Cannabis-Biocare.html
Midas Letter on RavenQuest RavenQuest BioMed Establishes a Solid Base in What is Set to Become the Biggest Cannabis Market in the World 5 September 2019 https://midasletter.com/2019/09/rav...ome-the-biggest-cannabis-market-in-the-world/
Looks like we might have seen the bottom. RQB has lots of potential imo. Bought some more shares in the past week.
Thanks for the reminder. It is always difficult to precisely predict when a stock has possibly hit a bottom or not. As a result you have to read every comment on a message board with caution. Obviously this stock seems to have now hit rock bottom. Looking back, I think in partuclar two things can be learned from this: Stay away from drugs It is better to sell at some point even if it results in a big loss. This way you have a chance to maybe get your money back with 2-3 successful trades with a company in a similar risk/reward category.
